PRICE FLUCTUATIONS ACROSS LIFECYCLE- INSIGHTS FROM THE ANTI-VEGF MARKET

Author(s)

Chriv E, Carr DR, Anastasaki E, Bradshaw SE
Market Access Solutions Ltd, London, UK

OBJECTIVES: To analyze the impact of indication expansion and market competition on anti-VEGF drug prices in the United Kingdom, France and Germany, with a view to understanding implications for lifecycle management. METHODS: Secondary research was conducted to identify approved indications and official list prices from the British National Formulary, the French Assurance Maladie database and the German Rote List for ranibizumab (Lucentis, Roche) and aflibercept (Eylea, Bayer) from launch to 2015. Indications were reviewed based on the EMA and individual countries’ official journals. Annualized treatment costs were calculated based on the official list prices and compared across countries and over time. RESULTS: Ranibizumab was approved in 2007 for wet age-related macular degeneration (AMD). In 2010, 2011 and 2013, the list of indications expanded to include diabetic macular edema (DME), retinal vein occlusion and pathologic myopia, respectively. Aflibercept, another anti-VEGF treatment, gained EMA license in 2012 for wet AMD and for DME in 2014. Among countries, France has seen the biggest ranibizumab list price discount, with about 44% reduction between 2007 and 2015. In Germany, price of ranibizumab dropped by 15% in 2009 before aflibercept and dexamethasone (Ozurdex, Allergan) entered the market, and has since remained stable. Price of ranibizumab in the UK has remained stable since launch. Aflibercept launched at a 36% to 42% lower annual cost compared to ranibizumab across countries. So far prices remain stable. CONCLUSIONS: Due to different market characteristics, the impact of indication expansion on price varies across the markets in scope. Maintaining a high list price is complicated in price regulated countries. List prices are not affected by subsequent indications in free pricing markets, where contracting and confidential discounts are usually key for access. To maintain high list prices and avoid impact of international price referencing, patient access schemes may be potential options, but acceptability varies across countries.

Conference/Value in Health Info

2015-11, ISPOR Europe 2015, Milan, Italy

Value in Health, Vol. 18, No. 7 (November 2015)

Code

PSS73

Topic

Economic Evaluation

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies

Disease

Sensory System Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×